Search Results - "Port, Martha"

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial by Reuter, Uwe, Lucas, Christian, Dolezil, David, Hand, Austin L., Port, Martha D., Nichols, Russell M., Stroud, Chad, Tockhorn-Heidenreich, Antje, Detke, Holland C.

“…Introduction Results from the open-label extension of the phase 3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a…”
Get full text

Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo‐controlled study by Lipton, Richard B., Buse, Dawn C., Sandoe, Claire H., Ford, Janet H., Hand, Austin L., Jedynak, Jakub P., Port, Martha D., Detke, Holland C.

“…Objective To evaluate changes in interictal burden with galcanezumab versus placebo in patients with episodic (EM) or chronic migraine (CM). Background The…”
Get full text

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials by Loo, Li Shen, Ailani, Jessica, Schim, Jack, Baygani, Simin, Hundemer, Hans-Peter, Port, Martha, Krege, John H.

“…Objective To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background While…”
Get full text

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine by Ford, Janet H., Kurth, Tobias, Starling, Amaal J., Ayer, David W., Wietecha, Linda A., Port, Martha D., Rettiganti, Mallikarjuna, Ruff, Dustin D.

“…Objective This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient‐reported outcomes…”
Get full text

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials by Stauffer, Virginia L., Turner, Ira, Kemmer, Phebe, Kielbasa, William, Day, Kathleen, Port, Martha, Quinlan, Tonya, Camporeale, Angelo

“…Background Migraine clinical profile may change with age, making it necessary to verify that migraine treatments are equally safe and effective in older…”
Get full text

Differential stimulation‐induced receptor localization in lipid rafts for interleukin‐6 family cytokines signaling through the gp130/leukemia inhibitory factor receptor complex by Port, Martha D., Gibson, Robin M., Nathanson, Neil M.

“…Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are cytokines which signal through receptor complexes that include the receptor…”
Get full text

Transregulation of leukemia inhibitor factor receptor expression and function by growth factors in neuroblastoma cells by Port, Martha D., Laszlo, George S., Nathanson, Neil M.

“…The cytokines that signal through the leukemia inhibitory factor (LIF) receptor are members of the neuropoietic cytokine family and have varied and numerous…”
Get full text

PIRLs: A novel class of plant intracellular leucine-rich repeat proteins by Forsthoefel, N.R.(Whitman Coll., Walla Walla, WA (USA)), Cutler, K, Port, M.D, Yamamoto, T, Vernon, D.M

“…Leucine-rich repeat (LRR) proteins feature tandem Introduction leucine-rich motifs that form a protein-protein interaction domain. Plants contain diverse…”
Get full text

Does Wearing-Off of Efficacy Occur in Galcanezumab-Treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials (1922) by Ailani, Jessica, Kuruppu, Dulanji, Rettiganti, Mallikarjuna, Oakes, Tina, Wietecha, Linda, Port, Martha, Blumenfeld, Andrew

“…Abstract only…”
Get full text

Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment (1914) by Sandoe, Claire, Lipton, Richard, Buse, Dawn, Ford, Janet, Hand, Austin, Jedynak, Jakub, Port, Martha, Detke, Holland

“…Abstract only…”
Get full text

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials by Ailani, Jessica, Kuruppu, Dulanji K., Rettiganti, Mallikarjuna, Oakes, Tina, Schroeder, Krista, Wietecha, Linda, Port, Martha, Blumenfeld, Andrew M.

“…Objective The purpose of this study was to propose a definition of “wearing off” at the individual patient‐level and determine the percentage of patients with…”
Get full text

Effect of Age on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine (P2.10-021) by Stauffer, Virginia L., Turner, Ira, Kemmer, Phebe, Port, Martha, Day, Kathleen, Camporeale, Angelo

“…Abstract only…”
Get full text

Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine (P1.10-003) by Ruff, Dustin, Ford, Janet, Starling, Amaal, Detke, Holland C., Nichols, Russell, Port, Martha, Aurora, Sheena K.

“…Abstract only…”
Get full text

Differential stimulation-induced receptor localization in lipid rafts for interleukin-6 family cytokines signaling through the gp130leukemia inhibitory factor receptor complex by Port, Martha D, Gibson, Robin M, Nathanson, Neil M

“…Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are cytokines which signal through receptor complexes that include the receptor…”
Get full text

Neurokine receptors and lipid rafts by Port, Martha D, Gibson, Robin M, Nathanson, Neil M

“…Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are cytokines which signal through receptor complexes that include the receptor…”
Get full text

Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cells by Port, Martha D, Laszlo, George S, Nathanson, Neil M

“…The cytokines that signal through the leukemia inhibitory factor (LIF) receptor are members of the neuropoietic cytokine family and have varied and numerous…”
Get full text

Regulation of expression and function of neurokine receptors by Port, Martha D

“…Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are cytokines which signal through receptor complexes that include the subunits gp130…”
Get full text

Regulation of expression and function of neurokine receptors by Port, Martha D

“…Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are cytokines which signal through receptor complexes that include the subunits gp130…”
Get full text